Terms: = Lymphoma AND SH2B3, LNK, 10019, ENSG00000111252, Q9UQQ2 AND Diagnosis
3 results:
1. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
2. Immune dysregulation associated with co-occurring germline CBL and sh2b3 variants.
Baccelli F; Leardini D; Muratore E; Messelodi D; Bertuccio SN; Chiriaco M; Cancrini C; Conti F; Castagnetti F; Pedace L; Pession A; Yoshimi A; Niemeyer C; Tartaglia M; Locatelli F; Masetti R
Hum Genomics; 2022 Sep; 16(1):40. PubMed ID: 36123612
[TBL] [Abstract] [Full Text] [Related]
3. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract] [Full Text] [Related]
